Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06313086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

StatusRecruiting
PhasePhase 3
Started2024-03-13
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 10, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-05-08
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-03→confirmed 2024-03-13
Study sites0→1
2024-03-14
minor
Original filing
A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer
Trial Details
NCT Number NCT06313086
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions HER2-positive Breast Cancer
Enrollment 442 participants
Start Date 2024-03-13
Primary Completion 2025-12 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2024-05-10